Skip to main content

Leiomyosarcoma & Other Uterine Sarcomas

The majority of endometrial cancers are carcinomas, which are cancers that form in the tissues that line internal organs such as the uterus. Some women, however, develop a type of cancer called a uterine sarcoma. These cancers start in the muscle or other connective tissues that surround the uterus -- in a layer called the myometrium.

For more, visit this link:

Low grade ESS, a study in 14 cases

Low grade Endometrial Stromal Sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases

Tahereh Ashraf-Ganjoei, Nadereh Behtash, Mamak Shariat and Asamosadat Mosavi

Gynecologic Oncology Department, Vali Asr Hospital, Keshavarz Blvd., Tehran 14194, Iran

World Journal of Surgical Oncology 2006, 4:50doi:10.1186/1477-7819-4-50

The electronic version of this article is the complete one and can be found online at:

Published: 9 August 2006


Endometrial stromal sarcoma (ESS) is a rare disease with probably less than 700 new cases in the USA or Europe per year. The aim of this study was to evaluate the behavior of low-grade endometrial stromal sarcoma (LGESS) in relation to their clinical and pathological features and to identify possible prognostic factors.

Patients and methods

Fourteen patients with histologically proven ESS were included in the analysis. Endometrial stromal sarcoma is characterized by proliferations composed of cells with Endometrial stromal cell differentiation. Low-grade endometrial stromal sarcoma has an infiltrating margin and typically show extensive worm-like vessel invasion.

New FIGO staging for carcinoma of the vulva, cervix, endometrium, and sarcomas

The International Federation of Gynecology and Obstetrics (FIGO) staging systems for vulva, cervix, endometrium, and sarcomas have been revised for the first time in over a decade. The purpose of the staging system is to provide uniform terminology for better communication among health professionals and to provide appropriate prognosis to the patients which results in treatment improvement. This is a constantly evolving process as new therapeutic modalities are developed, new imaging and surgical approaches are applied, and more prognostic information becomes available. The previous system did not reflect the prognosis in some patient subsets where medical research and practice have shown explosive growth of new knowledge in recent years.

Read full article

Survival rates for Uterine Sarcoma, by stage

Survival rates are often used by doctors as a standard way of discussing a person's prognosis (outlook). Some patients with cancer may want to know the survival statistics for people in similar situations, while others may not find the numbers helpful, or may even not want to know them.

The 5-year survival rate refers to the percentage of patients who live at least 5 years after their cancer is diagnosed. Of course, many people live much longer than 5 years (and many are cured).

Understanding a Pathology Report

Source: People Living With Cancer

All cancers are diagnosed by providing a sample of a patient's tumor to a specialized medical doctor called a pathologist. The pathologist microscopically examines the sample, or biopsy, and provides a written report to the oncologist or treating doctor. The pathologist provides a disease diagnosis, and this information forms the basis of cancer treatment.

Despite the complex medical language used in the pathology reports, the reports can be understood with help from the oncologist. A person is entitled by law to a copy of his or her pathology report, and this copy can be used when seeking a second opinion to develop treatment options. Ultimately, treatment of a patient's cancer depends on what he or she and the oncologist feel is the best interpretation of the pathology report.

To read the complete article and find additional resources, visit this link